Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Study of Efficacy and Safety of HRS-2261 in Refractory Chronic Cough
Conditions
Interventions
HRS-2261 oral tablet
Matching placebo to HRS-2261
Locations
1
China
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Start Date
March 9, 2023
Primary Completion Date
March 5, 2024
Completion Date
March 5, 2024
Last Updated
January 21, 2026
NCT05599191
NCT05628740
NCT03282591
NCT02349425
Lead Sponsor
Guangdong Hengrui Pharmaceutical Co., Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions